In people with group 1 pulmonary arterial hypertension, how do phosphodiesterase type 5 inhibitors (PDE5i) compare with endothelin receptor antagonists (ERAs)?

Cochrane Clinical Answers 2026

View at publisher

Authors: Bipin Thapa

DOI: 10.1002/cca.4706

Cited by: 0

References: 1

Fields of Study & Subjects

Pulmonary Hypertension Research and Treatments Phosphodiesterase function and regulation Vascular Anomalies and Treatments

References 1